MedTrace Logo

Bioavailability Study of Famotidine Tablets 40 mg Under Fasting Conditions

NCT01511731 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2012-01-19

No results posted yet for this study

Summary

The objective of this study was to compare the single-dose relative bioavailability of Reddy Cheminor and Merck \&Co, pepcid 40 mg famotidine tablets under fasting conditions.

Conditions

  • Healthy

Interventions

DRUG

Famotidine

Famotidine Tablets 40 mg

DRUG

Pepcid

40mg tablets

Sponsors & Collaborators

  • Dr. Reddy's Laboratories Limited

    lead INDUSTRY

Principal Investigators

  • Samuel Serfaty, MD · Phoenix Clinical Research Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
1998-10-31
Primary Completion
1998-10-31
Completion
1998-10-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01511731 on ClinicalTrials.gov